This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Sabcomeline

Upsher-Smith Laboratories Inc.

Drug Names(s): Memric, SB-202026, BCI-224

Description: Sabcomeline is a functionally selective muscarinic M1 receptor partial agonist.

When sabcomeline was combined with an on-market serotonin reuptake inhibitor (SSRI) in animal behavioral models measuring effects on mood and cognition, it showed strong activity and increased neurogenesis, suggesting that there is a synergistic response.

Deal Structure: Minster and GlaxoSmithKline
In 2001, Minster Pharma, originally named BioPartners, was established when it acquired from GlaxoSmithKline the worldwide development rights for tonabersat and sabcomeline.

Proximagen and Minster
In January 2010, the Boards of Proximagen and Minster announced that they reached agreement on the terms of a recommended cash offer by Proximagen for the entire issued and to be issued share capital of Minster. The acquisition was closed in March 2010.

BrainCells and Proximagen
In August 2010, BrainCells announced that it has signed an agreement with Proximagen Group to acquire sabcomeline. Under the terms of the agreement, BrainCells will pay Proximagen an upfront fee and development and sales milestone payments together worth up to $51 million, as well as a royalty on sales, for worldwide development and commercial rights to the compound.

Upsher-Smith and Proximagen
In June 2012, Upsher-Smith announced agreed to...See full deal structure in Biomedtracker

Partners: BrainCells Inc.


Sabcomeline News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug